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MicroRNAs in skeletal muscle: their role and regulation
in development, disease and function
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Maintaining skeletal muscle function throughout the lifespan is a prerequisite for good health
and independent living. For skeletal muscle to consistently function at optimal levels, the
efﬁcient activation of processes that regulate muscle development, growth, regeneration and
metabolism is required. Numerous conditions including neuromuscular disorders, physical
inactivity, chronic disease and ageing are associated with perturbations in skeletal muscle
function. A loss or reduction in skeletal muscle function often leads to increased morbidity and
mortalityeitherdirectly,orindirectly,viathedevelopmentofsecondarydiseasessuchasdiabetes,
obesity, cardiovascular and respiratory disease. Identifying mechanisms which inﬂuence the
processes regulating skeletal muscle function is a key priority. The discovery of microRNAs
(miRNAs) provides a new avenue that will extend our knowledge of factors controlling skeletal
muscle function. miRNAs may also improve our understanding and application of current
therapeutic approaches as well as enable the identiﬁcation of new therapeutic strategies and
targets aimed at maintaining and/or improving skeletal muscle health. This review brings
togetherthelatestdevelopmentsinskeletalmusclemiRNAbiologyandfocusesontheirroleand
regulation under physiological and patho-physiological conditions with an emphasis on: myo-
genesis, hypertrophy, atrophy and regeneration; exercise and nutrition; muscle disease, ageing,
diabetes and obesity.
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Introduction
Skeletal muscle makes up approximately 40% of the
body’s mass. The principal function of skeletal muscle
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is contraction-related in order to control movement and
posture, a process generally requiring the oxidation of
nutrients delivered to the body through the diet. Skeletal
muscle has a unique ability to adapt to changes in
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its environment. In response to increased use through
regular exercise training, skeletal muscle can increase its
size and capacity to produce force (Fry, 2004), improve
its resistance to fatigue and enhance its oxidation of
carbohydrates and fats (Coyle, 2000). In contrast, ageing,
sedentary lifestyles and immobilization, as well as neuro-
muscular disorders (Lynch, 2001) and chronic disease
conditions (Jagoe & Goldberg, 2001; Di Giovanni et al.
2004;Tisdale,2004;Doucetetal.2007)areassociatedwith
the loss of skeletal muscle mass and function. Reduced
muscle size and contraction have negative consequences
forskeletalmusclecarbohydrateandfatmetabolism(Stein
& Wade, 2005) which increases the risk of metabolic
disorders (Corpeleijn et al. 2009). The important role of
musclemassandfunctioninnumerousdiseaseconditions
underpins the necessity of understanding the molecular
factors which control skeletal muscle development over
the entire lifespan, from embryonic, postnatal and adult
development, through to the changes which occur in the
elderly.TherecentidentiﬁcationofmicroRNAs(miRNAs)
has opened up a new ﬁeld of investigation to under-
stand the molecular processes which control numerous
disease states (Croce & Calin, 2005; Pandey et al. 2009;
Pauley et al. 2009; Saal & Harvey, 2009). This review will
highlight our present understanding of skeletal muscle
miRNA regulation and how miRNAs may control skeletal
muscle development, function and adaptation.
What are miRNAs?
miRNAs are small (∼20–30 nucleotides (nt)) non-coding
ribonucleicacids(RNAs)whicharehighlyconservedfrom
plants to mammals (reviewed previously in Bartel, 2004).
Presently their known functions are to inhibit protein
translation or enhance messenger RNA degradation
(Hamilton & Baulcombe, 1999; Reinhart et al. 2000).
miRNAs are initially transcribed in the nucleus as
long primary transcripts up to several kilobases long
which are known as primary miRNA (pri-miRNA)
(Bartel,2004).Theribonuclease(RNase)IIIendonuclease
Drosha associated with Pasha (also known as DGCR8)
cleaves the pri-miRNA into a ∼60–70nt intermediate
referred to as the miRNA precursor, or pre-miRNA
(Lee et al. 2003). Exportin-5 (XPO5) transports the
pre-miRNA from the nucleus to the cytoplasm (Lund
et al. 2004) where a second RNase III endonuclease,
Dicer1, cuts the pre-miRNA into a ∼22nt miRNA duplex
(Lee et al. 2003). One strand is degraded while the
other confers the mature miRNA. The latter is then
incorporated into a ribonucleoprotein complex known
as the RNA-induced silencing complex (RISC) (Schwarz
et al. 2002). This complex enables the identiﬁcation and
binding to the target mRNA resulting in its degradation
or repression of protein translation (Bartel, 2004). TRBP
(humanimmunodeﬁciencyvirustransactivatingresponse
RNA-binding protein) forms part of the RISC complex
(Chendrimada et al. 2005). Phosphorylation of TRBP
by the mitogen-activated protein kinase Erk increases
the stability of the RISC complex and enhances miRNA
production (Paroo et al. 2009). Individual miRNAs do
not act alone nor do they target only a unique gene.
Indeed, miRNAs have multiple gene targets and each
target may be regulated by multiple miRNAs (Lewis et al.
2003).
As most of this review paper discusses the roles and
regulationofthematuremiRNAtranscripts,‘miRNA’will
always refer to the mature form. When referring to the
primary miRNA transcript ‘pri-miRNA’ will be written,
while‘pre-miRNA’willbeusedwhendiscussingamiRNA
precursor.
miRNAs highly enriched in muscle
A suite of miRNAs, highly enriched in cardiac and/or
skeletal muscle (referred to as myomiRs), has recently
been identiﬁed and include miR-1, miR-133a, miR-133b,
miR-206, miR-208, miR-208b, miR-486 and miR-499
(McCarthy & Esser, 2007; Callis et al. 2008; van Rooij
et al. 2008, 2009; Small et al. 2010). Several of these
miRNAs are organized under bicistronic clusters on the
same chromosome (i.e. miR-1-1/133a-2, miR-1-2/133a-1
and miR-206/133b) and are transcribed together (Chen
et al. 2009; Liu & Olson, 2010). Regulation of these myo-
miRs is controlled by key myogenic regulatory factors
(MRFs), including myogenic differentiation1 (MyoD)
a n dm y o g e n i n( R a oet al. 2006; Rosenberg et al. 2006)
as well as myocyte enhancer factor 2 (MEF2) (Liu et al.
2007), serum response factor (SRF) (Chen et al. 2006)
and myocardin-related transcription factor-A (MRTF-A)
(Small et al. 2010). MyomiRs inﬂuence multiple facets
of muscle development and function through their
regulation of key genes controlling myogenesis (Chen
et al. 2006; Kim et al. 2006; Rao et al. 2006). miR-1 and
miR-133a also regulate SRF and MEF2 demonstrating the
existence of negative feedback loops (Chen et al. 2006).
Aberrant regulation of some of these muscle-enriched
miRNAs can disrupt intracellular signalling networks
(Elia et al. 2009; Small et al. 2010) which may result in
pathologicalconditions(Eisenbergetal.2009).Identifying
the role and regulation of skeletal muscle miRNAs during
various phases of muscle development, as well as in
healthyanddiseasedconditions,willsigniﬁcantlyenhance
our understanding of skeletal muscle biology and may
result in new therapies to target muscle diseases or
chronic diseases associated with impaired muscle growth,
regeneration or function. Additionally, understanding
miRNA biology and function will enhance our under-
standing and application of current therapies.
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miRNAs and myocyte proliferation and differentiation
Skeletal muscle development is a complex process
requiring coordination of multiple factors which govern
the proliferation of myoblasts, their exit from the cell
cycle and subsequent differentiation into multinucleated
myotubes (Buckingham, 2006). Myogenesis is mainly
controlled by several key transcription factors, including
the basic helix–loop–helix MRFs, myogenic factor 5
(Myf5), MyoD, myogenin and MRF4 (Berkes & Tapscott,
2005), as well MEF2 and SRF (Duprey & Lesens, 1994).
miRNAs have been shown to be involved in myo-
genesis(Zhao&Srivastava,2007)throughtheirregulatory
relationship with MRFs (Fig.1).
miR-133a increases myoblast proliferation, via its
repression of SRF (Chen et al. 2006), while
miR-1 stimulates myoblast differentiation via its
inhibition of histone deacetylase4 (HDAC4) (Chen
et al. 2006). Along similar lines, miR-206 further
inﬂuences the differentiation programme via an indirect
down-regulation of the helix–loop–helix protein Id, a
repressor of MyoD (Kim et al. 2006). miR-24 induces
cardiomyocyte hypertrophy in vitro and is up-regulated
during cardiac hypertrophy (van Rooij et al. 2006).
While miR-24 levels are maintained in adult terminally
differentiated cardiac and skeletal muscle, its precise
functional role in these tissues is unknown (Sun et al.
2008). The early stages of differentiation show an
up-regulation of miR-24 and its regulatory pattern
mimics that of differentiation-speciﬁc markers, such
as myosin heavy chain (MHC). Transforming growth
factor β (TGF-β)/Smad3 signalling inhibits miR-24,
resulting in the inhibition of differentiation (Sun et al.
2008). miR-181 is up-regulated at the onset of myo-
blast terminal differentiation with expression proﬁles
mimicking differentiation-speciﬁc genes such as creatine
kinase (Naguibneva et al. 2006). It was observed that
miR-181 may exert its pro-differentiation effects via its
inhibition of the homeobox protein Hox-A1; the latter a
protein which can inhibit MyoD expression (Yamamoto
& Kuroiwa, 2003). miR-27b targets the 3 -UTR of Pax3
leading to its down-regulation and early differentiation
(Crist et al. 2009). The inhibition of miR-27b maintains
Figure 1. microRNA regulation of muscle proliferation and differentiation
This ﬁgure shows the miRNAs and their targets regulated during proliferation (rectangle) and differentiation
(circles). miR-133a is increased during proliferation. It reduces serum response factor (SRF), which is known to
inhibit proliferation. miR-24 is up-regulated during early differentiation, and maintained during the latter stages of
differentiation. Its regulated targets are presently unknown. miR-27b enhances differentiation by targeting Pax3
which is known to stimulate muscle proliferation. miR-1 stimulates differentiation through its direct inhibition of
HDAC4, an inhibitor of differentiation, while miR-206 indirectly inhibits helix–loop–helix, the latter, a repressor
of MyoD. At the late stage of differentiation, miR-181a is increased and targets Hox-A11, a known inhibitor of
MyoD. miR-221/222 are decreased in differentiated myotubes. This removes its repression of p27 which is required
to inhibit proliferation. Outside symbols: → activates; —| inhibits; ? unknown target. Within symbols: ↑ increased;
↓ decreased.
C   2010 The Authors. Journal compilation C   2010 The Physiological Society4078 I. G¨ uller and A. P. Russell J Physiol 588.21
Pax3levels,leadstomoreproliferationanddelaystheonset
of differentiation. While some miRNAs are up-regulated
duringthetransitionfromproliferationtodifferentiation,
others,suchasmiR-221andmiR-222,aredown-regulated
(Cardinalietal.2009).DecreasesinmiR-221andmiR-222
are associated with increased expression of the cell cycle
inhibitor p27; the latter a direct target of both miR-221
andmiR-222.OverexpressionofmiR-221andmiR-222in
differentiating myotubes delays cell cycle withdrawal and
differentiation, a response associated with a reduction in
sarcomeric proteins (Cardinali et al. 2009).
The regulation between myogenic transcription factors
and various miRNAs is complex and appears to depend
on the cell cycle and fusion stages. Establishing the role
andregulationofmusclemiRNAswillenhanceourunder-
standingofembryonicandadultmuscledevelopmentand
regeneration.
miRNAs and muscle ﬁbre type
Human skeletal muscle consists of predominantly three
muscle ﬁbre types: I, IIa and IIx (also known as IIb). The
ﬁbretypesaregenerallyclassiﬁedassloworfast,depending
on their contractile characteristics, a reﬂection of the
expression of either the slow or fast contractile protein
isoforms of MHC (Schiafﬁno & Reggiani, 1996), and
metabolic characteristics, a reﬂection of mitochondrial
enzyme activities (Essen et al. 1975). TypeI ﬁbres (slow)
are recruited at low stimulation frequencies and function
oxidatively. In contrast, type IIx ﬁbres (fast) require high
stimulation frequencies and function glycolytically, while
type IIa ﬁbres (fast) possess intermediate characteristics
between type I and IIx ﬁbres. miR-208b and miR-499
are a part of a myomiR network that regulates MHC
expression, ﬁbre type and muscle performance (van
Rooij et al. 2007, 2009). miR-208b and miR-499 are
encoded in the introns of the mouse slow type I β-MHC
(Myh7) gene on chromosome 14 and mouse slow type
I MHC7b (My7b) gene positioned on chromosome2.
As such these miRNA/myosin networks share a positive
regulatory circuit which promotes a slow skeletal muscle
gene programme. This occurs, in part, through the
miR-208bandmiR-499targetingofseveraltranscriptional
repressors known to regulate muscle gene expression and
function including Sox6, Purβ, Sp3 (repressors of slow
muscle genes), HP-1β and Thrap1 (McCarthy et al. 2009;
van Rooij et al. 2009; Bell et al. 2010).
miRNAs and skeletal muscle hypertrophy and atrophy
Synergistic ablation, an intervention which increases
functional overload (FO), is often used to develop
hypertrophy of the plantaris muscle. Following 7days
of FO, mouse plantaris muscle mass increased by
45% with an associated change in several primary
miRNAs (pri-miR) and their corresponding mature
miRNA transcripts (McCarthy & Esser, 2007). While
pri-miR-1-2 and pri-miR-133a2 were increased 2-fold,
their mature transcripts, miR-1 and miR-133a, were
decreased by 50%. pri-miR-206 was increased 18.3-fold;
however, its mature transcript did not change (Fig.2A).
The reason for this discordant regulation between the
pri-miRNAs and their mature miRNA transcripts is
not clear. However, these observations may have been
inﬂuenced by the time of muscle sampling and future
time course experiments are required to determine
this. Alternatively, the functional-overload model may
have inﬂuenced mechanisms that control pri-mRNA
processing, such as RNA editing by ADAR (adenosine
deaminase, RNA speciﬁc) enzymes; a reaction known to
suppress pri-mRNA processing by Drosha, resulting in a
loss of the mature miRNA transcript (Yang et al. 2006).
The decrease in mature miR-1 and mature miR-133a
expression with FO may contribute to muscle hyper-
trophy. This suggests an additional function to their
previously identiﬁed roles in muscle differentiation and
proliferation,respectively(Chenetal.2006).Thepotential
of miR-1 and miR-133a to regulate multiple facets of
musclebiologymaydependuponthestimuluscontrolling
their activation. miR-1 and mature miR-133a may play
a role in muscle hypertrophy by the removal of their
transcriptional inhibition of growth factor gene targets,
including hepatocyte growth factor receptor (c-MET),
hepatocyte growth factor (HGF), leukaemia inhibitor
factor (LIF), insulin-like growth factor1 (IGF-1) and
SRF (McCarthy & Esser, 2007) (Fig.2A). Indeed, IGF-1
levels are increased in rat plantaris following overload
(Adams et al. 1999) while work from our laboratory
has shown that SRF levels are increased in human
skeletalmusclefollowinghypertrophy-inducingresistance
exercise (Lamon et al. 2009). Further evidence that a
regulatory loop between miR-1 and IGF-1 may regulate
muscle growth comes from recent observations made in
C2C12 myotubes and cardiomyocytes (Elia et al. 2009).
Increased levels of endogenous miR-1 in differentiating
C2C12 myotubes resulted in a reduction in the activation
ofanIGF-1luciferasereporterconstructandadecreasein
IGF-1proteinlevels.Conversely,IGF-1treatmentreduced
miR-1levelsinC2C12myotubes.IGF-1stimulatesC2C12
myotube hypertrophy via the activation of Akt signalling
and the inhibition of Forkhead (FoXO) transcription
factors (Rommel et al. 2001). Hypertrophied human
skeletal muscle also presents an increase in active Akt and
a reduction in FoXO levels (Leger et al. 2006a). miR-1
levels are reduced by active Akt and increased by active
FoXO3a (Elia et al. 2009) demonstrating a regulatory
loop whereby IGF-1 regulates miR-1 via an Akt/FoXO3a
pathway (Fig.2B); a pathway known to increase muscle
cell size (Latres et al. 2005). Furthermore, miR-1 levels
can be increased via FoXO3a which results in reduced
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IGF-1 protein levels and reduced Akt activity; a response
seen during myotube atrophy (Sandri et al. 2004; Latres
et al. 2005).
A direct genetic link has been observed between
miRNAs and muscle hypertrophy (Clop et al. 2006). The
enhanced muscular development of the Texel sheep has
been mapped to a single G-A mutation in the 3 -UTR of
the myostatin gene, a gene involved in the repression of
musclegrowth(Thomasetal.2000;McFarlaneetal.2006).
The mutation provides a novel binding site for miR-1 and
miR-206 which inhibits the translation of the myostatin
protein. The existence of polymorphic miRNA–target
interactions is of considerable interest and may help to
underpinmechanismsinvolvedincongenitalandacquired
myopathies.
Unloading of skeletal muscle, as caused by the micro-
gravity during spaceﬂight or via hind limb suspension
(HS), decreases muscle mass and force production
and shifts the muscle towards a glycolytic phenotype.
Following11daysofspaceﬂight,miR-206wassigniﬁcantly
decreased (Fig.3A) while miR-1 and miR-133a showed
a trend towards a reduction in mouse gastrocnemius
muscle (Allen et al. 2009). This was paralleled by an
increaseinthemuscleatrophyF-box(MAFbx;alsoknown
as atrogin-1) and myostatin, genes that are involved in
muscle atrophy (Bodine et al. 2001) and inhibition of
muscle growth (Morissette et al. 2009), respectively, and
increased in numerous models of muscle wasting (Glass,
2005; Leger et al. 2006b;D o u c e tet al. 2007; Leger et al.
2008). Whether miR-206 plays a direct or indirect role
in repressing these atrophy genes is unknown. miR-206
is up-regulated via MyoD (Chen et al. 2006), a protein
which can be degraded by MAFbx/atrogin-1 (Tintignac
etal.2005).ThepossibilitythatamiR-206/MyoD/MAFbx
regulatory loop exists which inﬂuences skeletal muscle
growth requires investigation.
miR-107, miR-208b, miR-221 and miR-499 were
signiﬁcantly down-regulated in rat soleus muscle
following 7days of HS-induced muscle atrophy; miR-23b
showed a tendency to be reduced (P =0.054) (McCarthy
et al. 2009) (Fig.3B). Unlike the space ﬂight model of
muscle atrophy, miR-206 was not decreased following HS
whichmaybeduetomethodologicaldifferencesincluding
species, muscle analysed and/or experimental duration.
Cytokines are known to increase protein degradation
and reduce protein synthesis (Menconi et al. 2007;
Tisdale, 2007). The pro-inﬂammatory cytokine TNF-like
weak inducer of apoptosis (TWEAK) has been
shown to cause muscle atrophy (Dogra et al. 2007).
TWEAK down-regulated several growth-related myo-
miRs,includingmiR-1,miR-23,miR-133a,miR-133band
miR-206 in C2C12 myotubes; however, it only reduced
miR-1, miR-133a and miR-133b in mouse skeletal muscle
in vivo (Panguluri et al. 2010) (Fig.3C). There was also an
increaseinmiR-455whichisalsoelevatedinseveralmuscle
dystrophies (Eisenberg et al. 2007). While treatment with
TWEAK regulates several muscle miRNAs involved in
musclegrowth,itisnotknownwhethertheirregulationis
a cause of muscle wasting or a response to prevent further
muscle wasting.
Figure 2. microRNA regulation of skeletal muscle hypertrophy
A, following functional overload-induced hypertrophy in mice, primary miR-1-2, -133a-2 and -206 are increased.
In contrast, the mature forms of miR-1 and miR-133a are decreased while miR-206 is unchanged. There is
also an increase in several growth-related genes that are predicted targets of these miRNAs; a cause and effect
relationship has not been conﬁrmed. ↑ increased; ↓ decreased; → unchanged; ←· ·→cause and effect unknown.
B, a regulatory loop exists in which Akt activation inhibits the FoXO3a transcriptional activation of miR-1. This could
remove the miR-1 repression of IGF-1 and potentially assist with muscle hypertrophy. → activates; —| inhibits.
C   2010 The Authors. Journal compilation C   2010 The Physiological Society4080 I. G¨ uller and A. P. Russell J Physiol 588.21
miRNAs and muscle regeneration
Skeletal muscle regeneration is a vital process required
to maintain healthy muscle mass, structure and function
throughout the adult life. While few studies have
investigated the miRNAs involved in regeneration,
miR-27, miR-1, miR-133, miR-206 and miR-188 are
potentialregulators.Inregeneratingadultmuscle,miR-27
is required to down-regulate Pax3 in order to promote
myogenesis, while its inhibition in injured muscle in
vivo delays muscle regeneration (Crist et al. 2009).
Following the laceration of rat tibialis anterior, an
injection of a cocktail of miRNAs including miR-1, -133
and -206 into the injured site enhanced regeneration
and prevented ﬁbrosis (Nakasa et al. 2009). This was
also associated with increases in the myogenic markers
MyoD, myogenin and Pax7; however, no cause and effect
relationship between these miRNAs, target genes and
muscle regeneration was determined. miR-181 increases
during muscle cell differentiation; however, it is expressed
at low levels in adult tissue except under conditions of
regeneration (Naguibneva et al. 2006). Presently the role
of miR-181 during regeneration has yet to be determined.
Identifying the miRNAs which enhance and/or inhibit
muscleregenerationhasimplicationsforthedevelopment
of potential therapeutic strategies for conditions with
compromised regeneration as seen in various muscle
dystrophies and in sarcopenia.
Inﬂuence of exercise on miRNAs
Exercise can reduce morbidity associated with chronic
disease, such as type2 diabetes (T2D) (Lanza et al. 2008),
cancer (Newton & Galvao, 2008) and cardiovascular
disease (Wisloff et al. 2005). At one end of the exercise
continuum is endurance exercise, commonly performed
at a moderate intensity with continuous or interval-based
repetitions. Repeated bouts of endurance exercise results
in increased mitochondrial content, capillary density and
enhanced capacity of the oxidation of carbohydrates and
lipids (Fluck, 2006; Joseph et al. 2006; Coffey & Hawley,
Figure 3. microRNAs and skeletal muscle atrophy
A, following spaceﬂight-induced atrophy in mice, a decrease in miR-206 has been observed as well as an increase in
myostatin and atrogin-1. A cause and effect relation between miR-206 and these targets has not been determined.
B, hind limb suspension decreases miR-107, -208b, -221, -499 and -23b in rat skeletal muscle; for miR-23,
P = 0.054. C, TWEAK increases protein degradation with an associated decrease in miR-23, miR-206, miR-1 and
miR-133a/b in C2C12 myotubes. TWEAK also reduces miR-1 and miR-133a/b and increases miR-455 in mouse
muscle in vivo. ↑ increased; ↓ decreased; ←· ·→cause and effect unknown.
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2007). Following 90min of exhaustive endurance exercise
(forced treadmill running) in mice, miR-1 and miR-181,
both thought to increase muscle differentiation and
development, as well as miR-107, were increased (Safdar
et al. 2009). miR-23 was decreased which correlated
with an increase in peroxisome proliferator-activated
receptor-γ coactivator-1α (PGC-1α)( S a f d a ret al.
2009) (Fig.4A), the latter a predicted target of this
miRNA (Wilfred et al. 2007). PGC-1α, a transcriptional
co-activator,regulatesnumerousskeletalmusclefunctions
including mitochondrial biogenesis, substrate oxidation,
muscle ﬁbre type (Russell, 2005) and recently, the
protection against muscle wasting (Sandri et al. 2006).
Four weeks of treadmill running endurance training
in mice resulted in an increase in miR-21 and a
decrease in miR-696, -709 and -720 (Aoi et al. 2010).
The decrease in miR-696 was negatively correlated with
PGC-1αproteinlevels.ThetransientelevationofmiR-696
in C2C12 myotubes did not inﬂuence PGC-1α mRNA
levels but did result in the suppression of PGC-1α
protein levels. Conversely, transfection of the myotubes
with a miR-696 inhibitor elevated PGC-1α protein
levels, without changing PGC-1α mRNA. While these
observations suggest that miR-696 may regulate PGC-1α
translation, no cause and effect has been established. To
datemiR-696and-709havenotbeenidentiﬁedinhumans
so the relevance of these observations to human skeletal
muscle development and function is unknown.
At the other end of the continuum is resistance exercise
which is commonly performed at high intensities for
shorter durations of time. This type of exercise has
an anabolic stimulus and it enhances muscle size by
increasing the synthesis of contractile and structural
proteins; as a result the muscle is often larger and also
more powerful (Fry, 2004; Leger et al. 2006a). Following
an acute bout of resistance exercise, performed by both
young and older men, pri-miR-1-2 and pri-miR-133a-1
were reduced in muscle biopsy samples taken from the
young subjects 6h post exercise (Drummond et al. 2008).
Pri-miR-133a-2 was reduced at 3 and 6h post exercise
in the older and young subjects, respectively. In contrast,
pri-miR-206wasincreasedat3and6hpostexerciseinthe
older and young subjects, respectively (Drummond et al.
2008). Of the mature miRNAs, only miR-1 was reduced
at 3 and 6h post exercise in the older and young subjects,
respectively; no changes in miR-133a or miR-206 were
observed (Fig.4B).
Thesestudiesshowthatexerciseiscapableofregulating
miRNA levels. It will be important to identify which
exercise-induced pathways alter miRNA expression and
how miRNA regulation contributes to the physiological
adaptations to exercise. Investigations that identify the
miRNAs responsible for exercise-induced adaptations, or
which can mimic some exercise-induced adaptations, will
signiﬁcantly advance the miRNA–muscle ﬁeld.
Inﬂuence of nutrition on miRNAs
The impact of ingesting essential amino acids (EAAs)
on skeletal muscle miRNA expression has also been
Figure 4. Inﬂuence of exercise on microRNAs
A,asingleboutofenduranceexerciseinmicereducesmiR-23aandincreasesmiR-1,-181,-107.Endurancetraining
increases miR-21 expression and decreases miR-696, -709, -720 expression in mice. A commonality between acute
endurance exercise and endurance exercise training is an increase in PGC-1α.P G C - 1 α is a predicted target for
miR-23a and miR-696. B, following a single bout of resistance exercise in men, miR-1 decreases with no changes
observed in miR-133a or miR-206. ↑ increased; ↓ decreased; → unchanged; ·· → cause and effect unknown.
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investigated (Drummond et al. 2009). Healthy males
ingested 10g of EAAs with muscle biopsies taken
before and 3h following. Analyses of microRNAs and
muscle-growth-related genes in the skeletal muscle
biopsies revealed an increase in miR-499, -208b, -23a, -1
and pri-miR-206, as well as MyoD1 and follistatin-like1
(FSTL1) mRNA, and a decrease in myostatin and MEF2C
expression (Fig.5). While EAAs can regulate muscle
miRNA and mRNA, no causal observations have been
determined.
The inﬂuence of elevated glucose levels on skeletal
muscle miR-1 and miR-133a was investigated in humans
following a 3h hyperglycaemic–euinsulinaemic clamp
(Granjon et al. 2009). Hyperglycaemia alone, in the
absence of hyperinsulinaemia, did not have an impact
on the expression levels of these two myomiRs. While no
study has investigated the effect of oral glucose ingestion
onskeletalmusclemiRNAlevels,theresultsfromGranjon
et al. (2009) suggest that any consequence of glucose
ingestion would be via an indirect effect of insulin.
miRNAs and skeletal muscle disease and dysfunction
Primary skeletal muscle disorders involve several groups
of diseases including muscular dystrophies,inﬂammatory
myopathies and congenital myopathies. While these
diseases can be deﬁned by their clinical and pathological
traitsthemolecularpathwaysinvolvedintheseconditions
are not well understood. With the evolution of miRNA
biology, studies have now begun to identify miRNA
signatures which are dysregulated in patient muscle
biopsies. Eisenberg and colleagues identiﬁed altered
Figure 5. Inﬂuence of EAAs on microRNAs
Essential amino acids increased miR-499, -208b, -23a, -1 and
pri-miR-206 levels in healthy males. This is associated with an increase
in MyoD1 and FSLT1 and a decrease in myostatin and MEF2C. A causal
link between these miRNAs and mRNAs has not been determined.
↑ increased; ↓ decreased; ←· ·→cause and effect unknown.
regulation of 185 miRNAs from 10 different muscle
disorders (Eisenberg et al. 2007). Of special interest were
miR-146b, miR-155, miR-214, miR-221 and miR-222,
which were increased in almost all of the samples
analysed. Of further interest will be identifying if, and
how, the regulation of these miRNAs contributes to the
pathophysiology of these muscle diseases.
Several studies have investigated the regulation of
miRNAs in patients with Duchene muscular dystrophy
(DMD), in the mdx mouse and the CXMDJ dog, two
animal models of muscular dystrophy, as well as in myo-
tonic dystrophy type1 (MD1) and type2 (MD2). Greco
et al. observed signiﬁcant increases in miR-31, -34c, -206,
-222, -223, -335, -449 and -494 and decreases in miR-1,
-29c and miR-135a in the quadriceps femoris muscles of
DMD patients and adductor muscles of mdx mice (Greco
et al. 2002). Similarly, Yuasa et al. observed that, miR-206,
but not miR-1, was increased in the tibialis anterior (TA)
muscle of mdx mice; however, both were reduced in the
TA muscle of the CXMDJ dog (Yuasa et al. 2008). In
vastuslateralismusclebiopsiesfrompatientswithMD1an
increaseinmiR-206,butnotmiR-1,-133a/bor-181a/b/c,
hasbeenobserved(Gambardellaetal.2010).However,the
suiteofmiRNAsmeasuredbyGrecoetal.,whichincluded
miR-206, were unchanged in biceps brachii biopsies from
patients with MD2 (Greco et al. 2002). The increase in
miR-206inMD1,butnotMD2,maybeduetothedifferent
musclesanalysedormaybeacharacteristicofthediseases.
In the mdx mousethereis muscle-speciﬁcregulationof
various miRNAs. When compared with control animals,
miR-206 expression is dramatically increased 4.5-fold in
the mdx diaphragm, decreased by 29% in the plantaris
muscle but unchanged in the soleus muscle (McCarthy
et al. 2007). miR-133a is modestly decreased by 23% in
the soleus muscle, but not in the plantaris, diaphragm
(McCarthy et al. 2007) or TA muscles (Yuasa et al. 2008).
The dramatic increase in miR-206 in mdx diaphragm is
of interest as this is the only muscle in the mdx mouse
which exhibits extensive and progressive degeneration,
ﬁbrosis and functional deﬁcits comparable to the limb
m u s c l e so fb o y sw i t hD M D( S t e d m a net al. 1991; Lynch
etal.1997).Thereasonforthedifferentregulatorypattern
of these miRNAs from one muscle group to another is
unclear;however,dystrophindeﬁciencyisknowntocause
muscle-speciﬁc responses in mice (Moens et al. 1993)
and humans (Webster et al. 1988; Khurana et al. 1995).
DifferencesinmiRNAregulationacrossspeciesmayrelate
to the severity of their respective dystrophic phenotypes
and relevance to the human DMD. For example, it is
generally agreed that the dystrophic phenotype of limb
musclesfromtheCXMDJdogisaverygoodrepresentation
of human DMD, while the mdx mouse presents a
much milder phenotype (Shimatsu et al. 2005; Banks &
Chamberlain, 2008). However, within the mdx mouse,
the diaphragm muscle does have an evolving dystrophic
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phenotypesimilartohumanDMDlimbmuscle(Stedman
et al. 1991).
miRNAs and age-related muscle wasting
The age-related loss of skeletal mass and function,
known as sarcopenia, is a key factor increasing falls
and fractures and reducing independent living. Elevated
levels of pri-miRNA-1-1, -1-2, -133a-1 and -133a-2, with
no change in pri-miR206, were observed in skeletal
muscle biopsies taken from six elderly (70±2y ears)
when compared with six younger (29±2y ears) men
(Drummond et al. 2008). However, there were no
differences in the mature miR-1 or miR-133a species.
Whether age-related alterations in miRNAs are a cause
or effect in humans in vivo is unclear. More studies
are required with larger sample sizes to establish if the
age-related changes in skeletal muscle are inﬂuenced by
aberrant miRNA expression and activity. Additionally, it
will be important to consider the potential inﬂuence of
physicalactivitylevelsandnutritionalstatus,factorswhich
can inﬂuence muscle miRNA levels, when comparing
young and older subjects.
miRNA and diabetes
Obesity and the metabolic syndrome are serious public
health problems,generating life-threatening diseases such
as atherosclerosis, cancer and type2 diabetes (T2D).
The involvement of microRNAs in obesity and T2D
has recently been reviewed with a focus on non-muscle
tissues such as pancreas, adipose tissue and liver (Lynn,
2009; Pandey et al. 2009; Heneghan et al. 2010). While
microRNAs play important roles in the regulation of
glucose and lipid metabolisms through the control of
pancreatic islet cell function, adipocyte proliferation and
differentiation and cholesterol biosynthesis, their role in
skeletal muscle function in diabetes and obesity is not
well established. To date only four papers have looked
at the consequences of insulin resistance on miRNA
expression in skeletal muscle of Goto-Kakizaki (GK) rats
(a rodent model of diabetes) (He et al. 2007; Huang
et al. 2009) as well as in T2D patients (Granjon et al.
2009; Gallagher et al. 2010). miRNA expression proﬁles,
analysed and compared from skeletal muscle of GK and
control rats, revealed the differential expression of 15
microRNAs (4 up- and 11 down-regulated; fold change
≥1.5). Interestingly, three out of the four up-regulated
miRNAs were paralogues of the miR-29 family. Northern
blot analyses conﬁrmed the increase in their expression in
three insulin-dependent tissues (i.e. skeletal muscle, liver
and fat) from diabetic GK rats, suggesting an association
betweenthismicroRNAfamilyandinsulinsensitivity(He
et al. 2007). A similar study determined the regulation
of miRNA expression in GK rats but observed slightly
different results (Huang et al. 2009). In this study nine
microRNAs were differentially expressed (2 up- and 7
down-regulated; fold change ≥2.0), with only miR-24
and miR-126 down-regulation conﬁrmed by Northern
blot analysis. Disparity in these results may have been
due to different microRNA extraction methods, probe
preparation and software used to identify the regulated
miRNAs in the microarrays. It should also be noted that
Huang et al. (2009) also observed a 3-fold increase in
p38 mitogen-activated protein kinase (MAPK) protein
levels. p38 MAPK is known to be a direct target of miR-24
(Kiriakidou et al. 2004). Further studies are necessary to
analyse the regulation of the insulin-responsive miR-29
family, the relationship between miR-24 and p38 MAPK
in diabetic skeletal muscle, as well as deﬁne their precise
role in the insulin signalling pathway.
To observe the impact of insulin on skeletal muscle
microRNA levels, vastus lateralis muscle biopsies were
taken from healthy subjects before and after a 3h
euglycaemic–hyperinsulinaemic clamp (Granjon et al.
2009). microRNA expression proﬁling showed that 39
microRNAs were down-regulated by insulin, including
the traditional myomiRs miR-1, miR-133a and miR-206.
Additionally,miR-29aandmiR-29c,microRNAsenriched
to insulin-sensitive tissues, such as muscle, liver and
adipose tissue, were also down-regulated. In contrast,
D r o s h aa n dD i c e r 1a sw e l la st h es e v e r a lA r g o n a u t e
proteinswereincreased.Theincreaseinthesecomponents
ofthemiRNAsynthesisandRISCpathwaysmaybeafailed
attempttomaintainmiRNAlevels.Insulindown-regulates
miR-1andmiR-133a,viatheactivationofsterolregulatory
element binding protein 1c (SREBP-1c) and its inhibition
of MEF2C, in human muscle cells in vitro (Granjon et al.
2009). Furthermore, the expression levels of miR-1 and
miR-133a are increased in an insulin-deﬁcient mouse
model induced by streptozotocin injection (Granjon et al.
2009).Inhumanskeletalmusclethebasalexpressionlevels
ofmiR-1andmiR-133awerenotdifferentwhencompared
between ﬁve healthy controls and ﬁve insulin-resistant
type2 diabetics (T2D) (Granjon et al. 2009). However,
insulin reduced miR-1 and miR-133a expression in the
healthy, but not in the T2D subjects. This response was
also associated with the inability of insulin to reduce
MEF2C expression in the diabetic patients. Along similar
lines, the expression levels of miR-1 were not different
when compared between 10 T2D patients, 10 impaired
glucose-tolerant patients (IGT) and 10 healthy controls
(Gallagher et al. 2010). However, this study did observe
a decrease in miR-133a and miR-206 in the T2D patients
when compared with the IGT and healthy subjects. Of
clinical interest was the signiﬁcant positive correlation
between miR-133a and fasting glucose levels and 2h
glucose tolerance, when all 30 subjects were analysed.
While a discrepancy with respect to the regulation of
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miR-133a between these studies is evident, the reason for
thisisnotclearandhighlightstheneedforfurtherresearch
in this area.
The role of miRNAs in obesity and diabetes has only
startedtobeexploredandfutureinvestigationwillunravel
their roles in metabolism and energy expenditure. Based
on recent observations the role and regulation of miRNAs
in rodent models of diabetes and obesity should be
considered with caution when potentially extrapolating
to human obesity and diabetes.
Conclusion
The emergence of the miRNA ﬁeld provides an exciting
opportunity to further understand the molecular factors
which control skeletal muscle development, regeneration
and function. miRNA biology also provides an avenue to
dissect the mechanisms which may contribute to genetic
and acquired muscle disorders and related complications.
The impact of behavioural choices inﬂuencing physical
activity and nutrition has an import role in determining
our longevity and quality of life. The observations
that exercise and nutrition may inﬂuence miRNA levels
has important implications for understanding how to
maintain health throughout the lifespan; an issue of
great relevance considering our ageing and sedentary
communities. Future studies will focus more on the
possibility of using miRNA as a therapeutic tool via gain
of function and loss of function experiments in muscle
c e l lm o d e l sa n di nr o d e n t s .A sw i t ha l lm o d e l so fg e n e t i c
manipulation issues such as target and tissue speciﬁcity
will be of major importance. Nevertheless, the potential
ofmiRNA-basedtherapiesoffersanexcitingandpowerful
alternative to attenuate and hopefully cure debilitating
muscle diseases.
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